LEVOTHYROXINE Drug Patent Profile
✉ Email this page to a colleague
When do Levothyroxine patents expire, and when can generic versions of Levothyroxine launch?
Levothyroxine is a drug marketed by Ani Pharms, Dr Reddys, Fresenius Kabi Usa, Maia Pharms Inc, Onesource Specialty, Ph Health, Piramal Critical, Xiromed, Zydus Pharms, Hikma, Accord Hlthcare, Amneal, Ascent Pharms Inc, Aurobindo Pharma, Lupin, Macleods Pharms Ltd, Merck Kgaa, Mylan, and Watson Labs Teva. and is included in twenty-one NDAs. There are seven patents protecting this drug.
The generic ingredient in LEVOTHYROXINE is levothyroxine sodium. There are ten drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Levothyroxine
A generic version of LEVOTHYROXINE was approved as levothyroxine sodium by MYLAN on June 5th, 2002.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LEVOTHYROXINE?
- What are the global sales for LEVOTHYROXINE?
- What is Average Wholesale Price for LEVOTHYROXINE?
Summary for LEVOTHYROXINE
| US Patents: | 0 |
| Applicants: | 19 |
| NDAs: | 21 |
| Drug Prices: | Drug price information for LEVOTHYROXINE |
| Drug Sales Revenues: | Drug sales revenues for LEVOTHYROXINE |
| What excipients (inactive ingredients) are in LEVOTHYROXINE? | LEVOTHYROXINE excipients list |
| DailyMed Link: | LEVOTHYROXINE at DailyMed |
US Patents and Regulatory Information for LEVOTHYROXINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ascent Pharms Inc | LEVOTHYROXINE SODIUM | levothyroxine sodium | TABLET;ORAL | 215259-006 | Jan 18, 2023 | AB4 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Macleods Pharms Ltd | LEVOTHYROXINE SODIUM | levothyroxine sodium | TABLET;ORAL | 211417-006 | Dec 21, 2022 | AB1,AB2,AB3,AB4 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Fresenius Kabi Usa | LEVOTHYROXINE SODIUM | levothyroxine sodium | SOLUTION;INTRAVENOUS | 210632-003 | Apr 11, 2019 | RX | Yes | Yes | 10,398,669 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
